MRK vs CRL
By Alex · Tickerpine
Merck & Company, Inc. vs Charles River Laboratories Inte, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | CRL |
|---|---|---|
| Price | $132.92 | $284.37 |
| Market cap | $327.94B | $13.70B |
| P/E ratio | 106.3 | — |
| ROE | 6.96% | -7.52% |
| Profit margin | 4.77% | -5.96% |
| Revenue growth | 5.10% | -2.70% |
| Dividend yield | 2.56% | — |
| Beta | 0.21 | 1.38 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs CRL in plain English
- MRK is the bigger company — about 23.9× the market cap of CRL.
- MRK earns a higher return on equity (7% vs -8%).
- MRK is growing revenue faster (5% vs -3%).
- MRK pays a dividend (2.56%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories Inte would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.